To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
12 Current news about the topic molecular partners
rss
Molecular Partners: Results from Phase I/II Clinical Trial of its anti-VEGF DARPin MP0112 in Diabetic Macular Edema
23-01-2013
Molecular Partners announced that the results of a Phase I/II study evaluating the safety and preliminary activity of MP0112, a long-acting anti-VEGF DARPin, in patients with Diabetic Macular Edema (DME) have been published in The American Journal of Ophthalmology (AJO). MP0112 was shown to ...
Allergan and Molecular Partners Enter into Exclusive Alliance
Global partnership will develop novel products for eye diseases
23-08-2012
Allergan, Inc. and Molecular Partners AG announced that they have significantly expanded their existing relationship by entering into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin® products for the treatment of serious ophthalmic ...
Molecular Partners AG appoints Chief Medical Officer
01-06-2012
Molecular Partners AG announced the appointment of Lisa Rojkjaer, MD as Chief Medical Officer, strengthening the existing management team.Dr. Rojkjaer holds a medical degree from the University of Toronto and is a board-certified hematologist with over 10 years experience in drug development ...
Molecular Partners comments on Allergan’s progress in Phase IIa Retinal Disease Trial using anti-VEGF DARPin
11-04-2012
Molecular Partners AG commented on the recent progress with its anti-VEGF DARPin (AGN-150998/MP0112), which is being developed in partnership with Allergan for ocular indications. Allergan announced last week at their R&D day that the compound successfully completed phase IIa development. ...
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc.
13-12-2011
Molecular Partners AG announced that it has entered into a strategic research collaboration and option agreement with Janssen Biotech, Inc. to research, discover and develop DARPin® products for the treatment of immunological diseases. The collaboration and expansion of its current agreement ...
Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal diseases
05-05-2011
Allergan, Inc. and Molecular Partners AG announced that they have entered into a license agreement for MP0112, a phase II proprietary therapeutic DARPin® protein targeting VEGF under investigation for the treatment of retinal diseases.Under the agreement, Allergan obtains exclusive global ...
Molecular Partners reports positive results from its first clinical studies
MP0112 is safe and effective in two separate phase I/IIa trials
02-05-2011
Molecular Partners AG announced that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A. The DARPin molecule was shown to be safe and well tolerated in two separate Phase I/IIa trials in wet age-related macular degeneration (wet AMD) and diabetic ...
Pepscan Therapeutics announces establishment of Scientific Advisory Board
30-09-2010
Pepscan Therapeutics announced the establishment of a Scientific Advisory Board (SAB). The SAB will guide the company in the further development and application of its core protein mimicking technology for the creation of novel therapeutic peptide drugs and monoclonal antibodies. The ...
Molecular Partners appoints Göran Ando as independent non executive board member
29-06-2010
Molecular Partners AG announced the appointment of Dr Göran Ando as independent non-executive member of the board of directors. Dr Ando brings considerable experience to the board of Molecular Partners, having been CEO of Celltech Group, plc. Prior to this, he was Executive Vice President ...
AMT Appoints New Chief Executive Officer
25-09-2009
Amsterdam Molecular Therapeutics announced the appointment of Jörn Aldag as its new Chief Executive Officer, starting October 5. Mr. Aldag has a strong record of accomplishments in the life sciences sector and more than twenty five years of experience in corporate management and finance. As ...
Netmeeting
